Sign In
Buy DOCS
$21.04
-0.470 (-2.19%)
At Close: Jun 03, 2026
Doximity (DOCS) Q3 Earnings and Revenues Top Estimates
06:15pm, Thursday, 06'th Feb 2025
Doximity (DOCS) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.29 per share a year ago.
Doximity shares soar 21% after company beats on revenue, raises fiscal year guidance
05:14pm, Thursday, 06'th Feb 2025
Doximity reported third-quarter fiscal 2025 results that beat analysts' expectations for revenue and guidance. The company's revenue increased 25% to $168.6 million in its third quarter.
Doximity Surpasses EPS, Revenue Goals
04:39pm, Thursday, 06'th Feb 2025
Doximity (DOCS 0.21%), a digital platform for U.S. medical professionals, released its fiscal third-quarter earnings on Feb. 6, 2025. The company reported impressive results, surpassing both analyst f
Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fourth Consecutive Year
04:02pm, Thursday, 06'th Feb 2025
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named 2025 Best in KLAS in the V
Doximity Announces Fiscal 2025 Third Quarter Financial Results
04:01pm, Thursday, 06'th Feb 2025
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 third quarter ended December 31, 20
Dr Martens recovery plan to be tested in forthcoming update
07:20am, Friday, 24'th Jan 2025
Dr Martens PLC (LSE:DOCS) shares have been rising recently, a rare event since the iconic boot maker listed in 2021. New chief executive Ije Nwokorie, ex-Wolff Olins and Apple, came with a lot of go
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
04:45am, Thursday, 23'rd Jan 2025
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency
12:56pm, Wednesday, 22'nd Jan 2025
Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR.
Doximity to Release Fiscal 2025 Third Quarter Results on February 6, 2025
04:01pm, Thursday, 16'th Jan 2025
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter e
Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution
06:51am, Monday, 13'th Jan 2025
Upgraded Doximity to a buy rating due to recent share price pullback, stronger engagement metrics, and deeper client relationships, creating a compelling entry point. DOCS reported 20% y/y revenue gro
Stock Picks From Seeking Alpha's December 2024 New Analysts
08:00am, Tuesday, 07'th Jan 2025
In December, we welcomed 29 new analysts to Seeking Alpha and in this article we are showcasing their stock picks and investment strategies. Five buy picks are highlighted on Viasat, Newmont, NeuroOne
5 Momentum Stocks to Buy for January After a Tepid December
09:36am, Monday, 06'th Jan 2025
Five stocks have strong momentum for January. These are: DOCS, LUV, ALK, DBX, PARRA.
3 Medical Services Stocks to Buy to Counter Labor Shortage Woes
04:31am, Friday, 03'rd Jan 2025
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most.
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow
10:11am, Tuesday, 24'th Dec 2024
Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-
Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note
07:21pm, Monday, 23'rd Dec 2024
Doximity (DOCS) closed the most recent trading day at $58.18, moving +0.61% from the previous trading session.
